Objective To investigate onthe correlation between the seven single nucleotide polymorphisms and genesis of T2DM. Methods High‐resolution melting (HRM ) curve technology was used to detect thegenotype of the seven SNPs in 202 T2DM patients and 200 healthy volunteers. The relationship between susceptible gene polymorphism and T 2DM was analyzed. Results The frequency of five SNP loci rs8050136 ,rs13266634 ,rs7578597 ,rs864745 and rs7961581 showed significant differences between T2DM patients and controls ( P< 0.01 ). The OR of rs8050136 ,rs13266634 ,rs757859 and rs864745 was >1 ,while OR of rs7961581 was <1. There was no significant difference in rs10811661 and rs10923931 loci between T2DM patients and controls (OR=1). Conclusion The polymorphism of loci rs8050136 ,rs13266634 ,rs7578597 and rs864745 is associated with T2DM genesis in this study population , while rs10811661 and rs10923931 is not associated with T 2DM genesis ,and rs7961581 may be a protective factor for T2DM.

OBJECTIVE： To investigate inhibitory effects of lupeol on the proliferation of human breast cancer MCF-7 cells and its possible mechanism. METHODS： Taking MCF-7 cells as research object， MTT assay was used to detect the proliferation of MCF-7 cells after treated with different doses of lupeol （7.5， 15， 30， 60， 90 mg/L） for 24 h. Survival rate and IC50 of MCF-7 cells were calculated. The inverted microscope and cell cloning experiment were used to observe and detect the morphological characteristics of MCF-7 cells and clonal colony formation after treated with different doses of lupeol （15， 30， 60 mg/L） for 24 h. The rate of clonal colony formation was calculated. MTT method and Western blotting assay were used to detect the proliferation of MCF-7 cells and the expression of related regulatory proteins （ERK1/2， p-ERK1/2， JNK， p-JNK， p38 MAPK， p-p38 MAPK） after additionally treated with MAPKs signaling pathway-related regulation protein inhibitors PD98059， SP600125 and SB203580. RESULTS： After treated with 15， 30， 60， 90 mg/L lupeol， survival rates of MCF-7 cells were decreased significantly （P＜0.05 or P＜0.01）. IC50 value of the compound was 52.94 mg/L. After treated with 15， 30， 60 mg/L lupeol， the morphological characteristics of cells in each group changed， and the phenomena of cell exfoliation， floating， solid shrinkage， roundness， volume reduction and necrosis were observed. The formation of clonal colony decreased and the rate of clonal colony formation decreased significantly （P＜0.05 or P＜0.01）. When lupeol used alone， compared with control group， survival rate （60 mg/L lupeol）of MCF-7 cells was decreased significantly； the expression of p-ERK1/2 （15， 30， 60 mg/L lupeol）， p-JNK （30， 60 mg/L lupeol） and p-p38 MAPK （30， 60 mg/L lupeol） were increased significantly （P＜0.05 or P＜0.01）. After additional use of relevant inhibitors， compared with 60 mg/L lupeol group， survival rates of MCF-7 cells in combination groups were increased significantly， while relative expression of p-ERK1/2， p-JNK and p-p38 MAPK were decreased significantly （P＜0.05 or P＜0.01）. CONCLUSIONS： Lupeol can inhibit the proliferation of human breast cancer MCF-7 cells， the mechanism of which may be related to the phosphorylation of MAPKs signaling pathway-related regulatory proteins.